measles, mumps, and rubella virus vaccine live + Comparator: Measles, Mumps, and Rubella Virus Vaccine Live
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Measles
Conditions
Measles, Mumps, Rubella, Varicella
Trial Timeline
Dec 1, 2001 → Jun 1, 2005
NCT ID
NCT00092404About measles, mumps, and rubella virus vaccine live + Comparator: Measles, Mumps, and Rubella Virus Vaccine Live
measles, mumps, and rubella virus vaccine live + Comparator: Measles, Mumps, and Rubella Virus Vaccine Live is a phase 2 stage product being developed by Merck for Measles. The current trial status is completed. This product is registered under clinical trial identifier NCT00092404. Target conditions include Measles, Mumps, Rubella.
What happened to similar drugs?
4 of 18 similar drugs in Measles were approved
Approved (4) Terminated (1) Active (13)
🔄Measles-Rubella vaccine (Live) I.P. (Freeze Dried) of M/s. Zydus Lifesciences Ltd + Yellow fever Vaccine (WHO prequalified)Zydus LifesciencesPhase 3
❌Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (ProQuad™) + M-M-R™ II and Varivax™MerckPhase 3
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00092404 | Phase 2 | Completed |
Competing Products
20 competing products in Measles